Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
View original at globenewswire.comMyriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI) SALT LAKE CITY, May 26, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The Prolaris + AI test is the only test where active surveillance metrics on patient results were built on studies with previously diagnosed, untreated patient cohorts.
60% confidenceAI-GUR is a statistically significant predictor of Gleason upgrade at first follow-up biopsy, independent of time elapsed since diagnosis and other clinical variables, and provides information not captured by conventional risk stratification tools or cribriform morphology.
60% confidenceThe predictive power of AI-GUR is robust across biopsy intervals, suggesting it may capture both disease progression and mischaracterization of the initial biopsy.
60% confidenceThe Prolaris Biopsy Test has already outperformed other biomarker tests in identifying appropriate patients for active surveillance in low and intermediate-risk populations.
60% confidencePATHOMIQ's AI image-based approach can deliver results within one day of receiving the digital images from the patient's biopsy or surgical sample.
60% confidenceProlaris + AI is the first and only prostate cancer biomarker test to unite clinical-pathological features, an independent molecular score, and independent AI-powered digital pathology technology.
60% confidenceProstate cancer is projected to be the leading cancer diagnosis in the U.S. in 2026, with more than 300,000 patients newly diagnosed. The Prolaris + AI Test introduces a valuable tool for active surveillance planning.
60% confidenceThe new AI metric will be available for all Prolaris Biopsy Tests performed on samples in the U.S. (other than from New York State) starting with tests processed on May 29, 2026. Approval for samples from New York State is expected to come soon.
60% confidence